A double blind trial with oxamniquine in chronic schistosomiasis mansoni
✍ Scribed by JoséRoberto Lambertucci; Dirceu B. Greco; Enio Roberto Pietra Pedroso; Manoel Otávio da; Costa Rocha; Herculano Mourão Salazar; Davidson Pires de Lima
- Publisher
- Elsevier Science
- Year
- 1982
- Tongue
- English
- Weight
- 550 KB
- Volume
- 76
- Category
- Article
- ISSN
- 0035-9203
No coin nor oath required. For personal study only.
📜 SIMILAR VOLUMES
Four hundred and eighty Chinese subjects with hepatitis B e antigen (HBeAg)-positive chronic hepatitis B (CHB) were enrolled in a multicenter, double-blind, randomized, placebo-controlled study of adefovir dipivoxil (ADV) 10 mg once daily. There was a significant difference in reduction of serum hep
Chronic hepatitis B and its life-threatening sequelae are highly prevalent in China. There is a need for effective new therapies to suppress hepatitis B virus (HBV) replication and ameliorate liver disease. In this study, we compared the efficacy of telbivudine, a nucleoside analogue, with lamivudin
CPG 10101, a synthetic oligodeoxynucleotide (ODN), is a toll-like receptor 9 (TLR9) agonist with antiviral and immunomodulatory properties that could potentially influence chronic infection with HCV. In this multicenter Phase 1b trial, 60 HCV-positive patients (50 genotype 1 HCV) were randomized and
Objective It has been proposed that a deficit of adenosinergic activity could contribute to the pathophysiology of schizophrenia. The authors undertook this study to further evaluate the level of adenosine deaminase (ADA) in patients with chronic schizophrenia treated with monotherapy of haloperidol